Oric Pharma CFO Dominic Piscitelli sells $189,390 in stock

Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), sold 14,000 shares of the company’s common stock on October 20, 2026, for a total value of $189,390. The shares were sold at a weighted average price of $13.5279, with individual transactions occurring within a price range of $13.50 to $13.65 per share.

The sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Piscitelli adopted on May 26, 2026. The transaction occurred as ORIC shares trade near their 52-week high of $14.68, with the stock delivering a 69% year-to-date return and a 30% gain over the past six months.

Prior to the sale, Mr. Piscitelli acquired 14,000 shares of common stock on the same day by exercising stock options at an exercise price of $4.36 per share, totaling $61,040. Following these transactions, Mr. Piscitelli directly holds 69,828 shares of Oric Pharmaceuticals common stock. He also beneficially owns 64,500 stock options, which grant the right to buy additional shares. According to InvestingPro analysis, ORIC currently appears overvalued relative to its Fair Value, though analysts maintain price targets ranging from $14 to $27 per share.

In other recent news, ORIC Pharmaceuticals has been the focus of significant analyst attention. BTIG initiated coverage on the company with a Buy rating and set a price target of $26. This reflects confidence in ORIC Pharmaceuticals’ development programs, including rinzimetostat and enozertinib. Additionally, H.C. Wainwright raised its price target for ORIC Pharmaceuticals from $25 to $27, maintaining a Buy rating. The firm highlighted the company’s progress in its pipeline, particularly noting upcoming updates for ORIC-944. These developments indicate a catalyst-rich second half of 2026 for the company. Both analyst firms are optimistic about ORIC Pharmaceuticals’ future prospects.